The first clinical applications of radiometabolic therapy date back to the fifties; since then this therapeutic tool has become widely used and its indications have been progressively extended. Today the main fields of application of radiometabolic therapy are oncology and the treatment of hyperthyroidism. The treatment of painful bone metastases, especially from breast and prostate cancer, is gaining importance and efficacy; indeed, pain associated with this type of lesions can be stopped for several months. In the near future, the availability of a wide variety of radiopharmaceutical substances should allow the clinician to choose specific radiocompounds for selected bone metastases. Some unresolved problems remain regarding radioimmunotherapy and the treatment of neuroendocrine tumors; as to the former, there are still many questions concerning the most suitable antibodies and radionuclides; as to the latter, it is still not clear in which phase of the therapeutic course this type of treatment should be inserted. Radiometabolic therapy of hyperthyroidism and differentiated thyroid cancer are both well established. 1311 radiometabolic treatment of different forms of hyperthyroidism has an excellent outcome, especially in patients with toxic nodular goiter; usually a single treatment is sufficient and only in exceptional cases is a second treatment needed. 1311 administration is certainly the most effective therapy in the management of residual disease and metastases of thyroid cancer that are able to accumulate iodine; noteworthily, about 75% of differentiated thyroid cancers have this capacity.
|Translated title of the contribution||Therapeutical applications|
|Number of pages||19|
|Publication status||Published - 1999|
ASJC Scopus subject areas